Actively Recruiting
An Evaluation of Dose-escalation for Intrathoracic Tumours
Led by Chris Goodman · Updated on 2026-02-04
141
Participants Needed
3
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a pragmatic trial with patients randomized between standard of care palliative thoracic radiation therapy (RT) vs. hypofractionated, dose-escalated, esophageal-sparing (HD-ES) intensity modulated radiation therapy (IMRT). The investigators hypothesize that the use of advanced radiation planning techniques to optimize dose to esophagus will permit the safe delivery of a modestly dose-escalated five-fraction course of palliative radiation to intrathoracic malignancies. This approach aims to deliver higher biologically effective doses while improving toxicity when compared to conventional approaches with the goal of prolonging high-quality overall survival.
CONDITIONS
Official Title
An Evaluation of Dose-escalation for Intrathoracic Tumours
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Intrathoracic tumour requiring palliative radiation, either for palliation of symptoms or prevention of progression that is expected to cause symptoms in the next 6 months (in the judgement of the enrolling investigator)
- Willingness and ability to provide informed consent
- Eastern Cooperative Oncology Group performance status 0-3
- Age 18 years or older
- Prior or planned systemic treatment (chemotherapy, immunotherapy, targeted agents) is permissible at the discretion of the treating medical oncologist
- Concurrent palliative radiotherapy to other metastatic sites is permissible at the discretion of the treating radiation oncologist.
- Life expectancy greater than 3 months
You will not qualify if you...
- Prior thoracic radiotherapy which, in the opinion of the treating of radiation oncologist, precludes the delivery of further thoracic radiotherapy. If there has been prior thoracic radiotherapy, a composite of all RT plans must be created, and the dose constraints herein must still be met. An allowance for 10 percent repair is permitted if at least 12 months have passed between the prior radiotherapy and the trial protocol specified radiotherapy.
- Serious medical comorbidities which, in the opinion of the treating radiation oncologist, preclude the delivery of radiotherapy. This includes interstitial lung disease.
- Pregnant or lactating women
- Inability to attend the full course of radiotherapy or planned follow-up visits
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
British Columbia Cancer Agency Center for the Southern Interior
Kelowna, British Columbia, Canada, V1Y5L3
Actively Recruiting
2
London Health Sciences Center Research Institute (Formerly Lawson Research Institute)
London, Ontario, Canada, N6A 4L6
Actively Recruiting
3
Waterloo Regional Health Network
Waterloo, Ontario, Canada
Actively Recruiting
Research Team
C
Christopher Goodman, MD
CONTACT
D
David Palma, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here